{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:28:00Z","timestamp":1783441680404,"version":"3.54.6"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T00:00:00Z","timestamp":1358208000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0054126","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T22:22:10Z","timestamp":1358288530000},"page":"e54126","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Poly(I:C)\/Alum Mixed Adjuvant Priming Enhances HBV Subunit Vaccine-Induced Immunity in Mice When Combined with Recombinant Adenoviral-Based HBV Vaccine Boosting"],"prefix":"10.1371","volume":"8","author":[{"given":"Xia","family":"Chuai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,1,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"FV Chisari","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"B Rehermann","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection\u2013natural history and clinical consequences","volume":"350","author":"D Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"ref4","first-page":"232","article-title":"Treatment of chronic hepatitis B. Lancet Infect Dis","volume":"1","author":"MF Yuen","year":"2001"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2010.12.031","article-title":"Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges","volume":"54","author":"ML Michel","year":"2011","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1586\/egh.09.48","article-title":"Therapeutic vaccination and novel strategies to treat chronic HBV infection","volume":"3","author":"A Bertoletti, Gehring","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.4049\/jimmunol.152.3.1110","article-title":"Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo","volume":"1529","author":"R Schirmbeck","year":"1994","journal-title":"J Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"F Steinhagen","year":"2010","journal-title":"Vaccine"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2008-07-019307","article-title":"TLRs and innate immunity","volume":"113","author":"BA Beutler","year":"2009","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.smim.2003.10.006","article-title":"Toll-like receptors and acquired immunity","volume":"16","author":"C Pasare","year":"2004","journal-title":"Semin Immunol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.vaccine.2007.12.010","article-title":"CpG motif based adjuvant as a replacement for Freund\u2019s complete adjuvant in a recombinant LHRH vaccine","volume":"26","author":"VA Conforti","year":"2008","journal-title":"Vaccine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.4049\/jimmunol.179.10.6889","article-title":"Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming","volume":"179","author":"DF Hoft","year":"2007","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/eji.1830270931","article-title":"CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants","volume":"27","author":"GB Lipford","year":"1997","journal-title":"Eur J Immunol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.4049\/jimmunol.1103811","article-title":"Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer","volume":"188","author":"G Forte","year":"2012","journal-title":"J Immunol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e1000373","DOI":"10.1371\/journal.ppat.1000373","article-title":"Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques","volume":"5","author":"C Stahl-Hennig","year":"2009","journal-title":"PLoS Pathog"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20090247","article-title":"Dendritic cells requirea systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant","volume":"206","author":"MP Longhi","year":"2009","journal-title":"J Exp Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e43730","DOI":"10.1371\/journal.pone.0043730","article-title":"Optimisation of Prime\u2013Boost Immunization in Mice Using Novel Protein-Based and Recombinant Vaccinia (Tiantan)-Based HBV Vaccine","volume":"7","author":"H Chen","year":"2012","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"MO Lasaro","year":"2009","journal-title":"Mol Ther"},{"key":"ref19","first-page":"506","article-title":"Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes. Virol J","volume":"8","author":"J Guan","year":"2011"},{"key":"ref20","first-page":"312","article-title":"The physicochemical and biological properties of SS1 fusion antigen of HBsAg secreted by mammalian cells","volume":"18","author":"SF Tian","year":"2002","journal-title":"Chin J Virol"},{"key":"ref21","first-page":"74","article-title":"Impact of different adjuvant on immunogenicity of HBV particle vaccine containing the S+PreS1 fusion antigen in Balb\/C mice","volume":"26","author":"H Chen","year":"2010","journal-title":"Chin J Biotech"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.vaccine.2008.02.063","article-title":"Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection","volume":"26","author":"L Bungener","year":"2008","journal-title":"Vaccine"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"AM Krieg","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1073\/pnas.93.7.2879","article-title":"CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFN-\u03b3","volume":"93","author":"DM Klinman","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4049\/jimmunol.160.2.870","article-title":"CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen","volume":"160","author":"HL Davis","year":"1998","journal-title":"J Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1743-422X-8-78","article-title":"Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine","volume":"8","author":"X Zhang","year":"2011","journal-title":"Virol J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/00002030-200404300-00007","article-title":"CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques","volume":"18","author":"D Verthelyi","year":"2004","journal-title":"AIDS"},{"key":"ref28","first-page":"1473","article-title":"CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults","volume":"AIDS19","author":"CL Cooper","year":"2005"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.vaccine.2004.07.014","article-title":"Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response","volume":"23","author":"CA Siegrist","year":"2004","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"CL Cooper","year":"2004","journal-title":"J Clin Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0264-410X(03)00045-8","article-title":"A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant","volume":"21","author":"SA Halperin","year":"2003","journal-title":"Vaccine"},{"key":"ref32","first-page":"20","article-title":"Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults","volume":"Vaccine24","author":"SA Halperin","year":"2006"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","article-title":"TLR3: Interferon induction by double-stranded RNA including poly(I:C)","volume":"60","author":"M Matsumoto","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.4049\/jimmunol.176.4.2074","article-title":"Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN","volume":"176","author":"A Le Bon","year":"2006","journal-title":"J Immunol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.4049\/jimmunol.176.8.4682","article-title":"Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming","volume":"176","author":"A Le Bon","year":"2006","journal-title":"J Immunol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10875-007-9087-x","article-title":"Toll or toll-free adjuvant path toward the optimal vaccine development","volume":"27","author":"KJ Ishii","year":"2007","journal-title":"J Clin Immunol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0054126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T18:23:55Z","timestamp":1687976635000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0054126"}},"subtitle":[],"editor":[{"given":"Lijun","family":"Rong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0054126","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,15]]}}}